Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
67.8M
-
Number of holders
-
52
-
Total 13F shares, excl. options
-
16.7M
-
Shares change
-
-415K
-
Total reported value, excl. options
-
$174M
-
Value change
-
-$6.13M
-
Number of buys
-
27
-
Number of sells
-
-21
-
Price
-
$10.36
Significant Holders of Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) as of Q4 2017
60 filings reported holding CRVS - Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q4 2017.
Corvus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (CRVS) has 52 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.7M shares
of 67.8M outstanding shares and own 24.72% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (5.38M shares), Novo Holdings A/S (3.24M shares), ADAMS STREET PARTNERS LLC (2.69M shares), FMR LLC (1.28M shares), EcoR1 Capital, LLC (588K shares), JENNISON ASSOCIATES LLC (467K shares), BVF INC/IL (459K shares), Rock Springs Capital Management LP (423K shares), Vanguard Group Inc (386K shares), and PRICE T ROWE ASSOCIATES INC /MD/ (306K shares).
This table shows the top 52 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.